Please assess the completion status of the following clinical trial:

Trial Title: Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent.~* Age \>= 18 years old.~* Metastatic breast cancer patients with lytic, sclerotic or mixed bone lesions.~* Non-symptomatic bone lesions, defined as pain absence, lack of bone complications (fracture, hypercalcemia, Central Nervous System (CNS) compression), no need of analgesic chronic administration for bone disease.~* A maximum of two chemotherapy lines for metastatic disease.~* A maximum of two hormone therapy lines for metastatic disease.~* Normal, minimally altered renal function (serum creatinine \< 1.5 x Upper Normal Limit (UNL)).~* Normal serum calcium levels.~* Performance status 0,1 (World Health Organization (WHO)).~* Negative pregnancy test before study recruitment.~Exclusion Criteria:~* Previous treatment with bisphosphonates or raloxifene in the 30 days prior to randomization.~* Metastasis in CNS.~* History of hypersensitivity to bisphosphonates.~* Pregnant or lactating women.~* Third chemotherapy line for metastatic disease.~* Third hormone therapy line for metastatic disease.~* Males.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: Zoledronic acid 4 mg (Type: EXPERIMENTAL): Zoledronate 4 mg every 3 or 4 weeks. This arm will receive study treatment from the time of entry into the trial, until the appearance of the symptoms of bone metastases (or a maximum period of 12 months, whichever occurs first).
- Arm B: Observation (Type: NO_INTERVENTION): Patients will not receive any treatment with bisphosphonates until the time of onset of symptoms (or a maximum period of 12 months, whichever occurs sooner).

Based on this trial design, predict the completion outcome and termination type (if applicable).